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Zusammenfassung 
Das Kolonkarzinom stellt sowohl in Deutschland als auch weltweit eine der häufigsten 
Ursachen für krebsassoziierte Todesfälle dar [1]. Bei Vorliegen von Metastasen ist die 
Therapie mit gegen den EGF-Rezeptor gerichteten Antikörpern (−EGFR) wie Cetuximab – 
neben Chirurgie, Radio- und Chemotherapie – eine wichtige Säule der Therapie [2]. 
Nebenwirkungen dieser Therapie in der Haut, welche als skin toxicity (ST) bezeichnet 
werden, können die Lebensqualität durch schwere acneiforme Hautausschläge – Skin Rash –
stark beeinträchtigen [3]. Es wurde eine statistische Assoziation zwischen einem erhöhten ST 
Schweregrad und der Überlebensdauer gezeigt [4]. Bisher existiert keine Möglichkeit das 
Auftreten von ST bei Patienten sicher vorherzusagen. Daher sind keine gezielten präventiven 
Maßnahmen oder Dosisanpassungen vor Therapiebeginn möglich. Auch gibt es keine 
etablierten prognostischen Marker für Überleben und Ansprechen von Patienten unter 
−EGFR Therapie.  
Auf Basis der Modellerkrankungen wurden im Rahmen dieser Arbeit DNA Polymorphismen 
(SNPs) in Zusammenhang mit 1) Acne vulgaris, 2) Systemischem Lupus erythematodes und  
3) Fc-Immunrezeptoren als mögliche Marker für ST identifiziert und mit Next-Generation-
Sequencing Ansätzen analysiert: 64 SNPs wurden in einem ‚training-set’ aus 16 Patienten mit 
ausschließlich hoch- oder geringgradiger ST und in einem ‚validation-set’ aus 55 Patienten 
aller ST-Schweregrade mit Hilfe des Ion Torrent PGM analysiert. 
In training- und validation-set konnte der bekannte Zusammenhang von ST und 
Überlebensdauer bestätigt werden. Eine Analyse der Assoziation der Genotypen mit ST-
Schweregraden zeigte eine signifikante Assoziation des SNPs rs849142 mit ST im trainings- 
(p=0,00395) und validation-set (p=0,04362). Ein signifikanter Zusammenhang von rs849142 
zum Überleben ließ sich in dem Patientenkollektiv jedoch nicht zeigen. 
Damit stellt rs849142 einen validierten potentiell prädiktiven Marker für den Schweregrad 
von ST bei −EGFR-Therapie des metastasierten kolorektalen Karzinoms dar.  
rs849142 ist ein SNP im JAZF1 (juxtaposed with another zinc finger protein 1) Gen. JAZF1 
fungiert als Transkriptionsrepressor [5], spielt eine Rolle im Lipid- und Glucosemetabolismus 
[6] und wird unter anderem von Blutzellen exprimiert. rs849142 wurde bereits im 
Zusammenhang mit dem Prostatakarzinom [7], dem systemischen Lupus erythromatodes [8] 
und der Lupus Nephritis [9] beschrieben.  
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Summary 
Colorectal cancer represents one of the most common causes of cancer-associated death in 
Germany and worldwide [1]. In metastatic stage, the use of monoclonal antibodies targeted at 
the EGF receptor (−EGFR) like Cetuximab is, besides surgery, radiotherapy and 
chemotherapy, an important therapy strategy [2]. 
Common adverse events of −EGFR therapy include severe acneiform rashes in the skin, are 
summarized as skin toxicity and often decrease patients’ quality of life. [3, 10]. A statistical 
association of severity of skin toxicity (ST) and survival has been found [4]. However, there 
is no established marker which can predict occurrence of ST. Consequently, preventive 
treatments or preventive dose-adjustments, which take the severity of ST into account, are 
difficult to carry out. Furthermore, there is no established prognostic marker for survival and 
response to −EGFR therapy.  
Based on model-diseases, this work identified DNA polymorphisms (SNPs) associated to  
1) acne, 2) systemic lupus erythematosus and 3) Fc-immunoreceptors as potential targets for 
testing of their association to ST in Next-Generation-Sequencing: 64 SNPs were analyzed in a 
‘training set’ consisting of 16 patients only with high or low grade ST and a ‘validation set’ 
consisting of 55 patients of with all ST severities utilizing the Ion Torrent PGM sequencer. 
In both sets the known association of ST with survival could be validated. An analysis of 
association SNPs with ST severity revealed the SNP rs849142 as significantly associated to 
ST in training (p=0.00395) and validation set (p=0.04362). However, rs841942 was not found 
to be significantly associated to survival in this patient collective. 
Therefore, rs849142 is a validated, potentially predictive marker for severity of ST in 
−EGFR therapy of metastatic colorectal cancer. rs849142 is a SNP in JAZF1 (juxtaposed 
with another zinc finger protein 1) gene. JAZF1 functions as transcription factor [5], 
influenced lipid- and glucose metabolism, [6] and is expressed by blood cells. rs849142 has 
been found to be associated to prostate cancer [7], systemic lupus [8] and lupus nephritis [9].  
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1. Introduction 
1.1 Metastatic Colorectal Cancer is one of the major causes of cancer related 
death in Germany 
Colorectal Cancer is among the first three types of malignant tumors with respect to new 
cases and cancer-related deaths in both the US [1] and Europe [11]. In its metastatic stage − 
referred to as metastatic colorectal cancer (mCRC) − pharmacological therapy focuses on 
chemotherapy (CTX), biologicals like antibodies targeting the epidermal growth factor 
receptor (EGFR) [2], vascular endothelial growth factor (VEGF) or radiotherapy, which is 
mostly used for treatment of rectal cancer. [12] 
The decision for targeted anti-EGFR-therapy (−EGFR) is personalized and predictive as 
efficacy of −EGFR therapy is limited to tumors without mutations (wild-type, WT) in the rat 
sarcoma (RAS) genes KRAS (Kirstin RAS) and NRAS (neuronal RAS) [13, 14]. Therefore, 
the approval authorities, EMA (European Medicines Agency) and FDA (Food and drug 
administration) granted the use of the two −EGFR directed antibodies Cetuximab (CET) 
and Panitumumab (PAN) only for mCRC characterized by a RAS-WT genotype. Despite 
improving response and survival rates, −EGFR agents often cause adverse effects in the skin 
termed skin toxicity (ST). 
1.2 -EGFR therapy associated skin toxicity decreases patients’ quality of life 
Adverse events associated with -EGFR therapies primarily present themselves as skin 
toxicity (ST) in the form of acneiform skin rash [15]. This results in the reduction of patients’ 
physical [16] and emotional well-being [10] as well as negative financial- and psychosocial 
effects [17]. Consequently, ST is treated by topical and systemic treatment with antibiotics 
like tetracycline and immune-response modulating drugs like methylprednisolone [15] 
dependent on its grade (Table 1). 
Grade 
of ST 
Description  
Consequences for 
treatment 
1 ‘Papules and/or pustules covering <10% BSA [body surface 
area], which may or may not be associated with symptoms 
of pruritus or tenderness’ 
No changes 
2 ‘Papules and/or pustules covering 10%-30% BSA, which 
may or may not be associated with symptoms of pruritus or 
tenderness; associated with psychosocial impact; limiting 
instrumental ADL [activities of daily living]’ 
Topical treatment 
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Table 1: Grading of skin toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) 4.0 [3] and 
grade-dependent treatment of acneiforme skin rash [15], Adopted from [3]. 
Taking the grade-dependence of -EGFR treatment into account, a predictive marker for ST 
would allow personalized preventive treatment of ST. Thus, patients without risk of 
developing ST would not receive any treatment of the skin thus avoiding interference of 
treatment with the therapy. In contrast, patients with a risk for high grade ST might receive 
intensified preventive treatment of ST allowing a more intensive -EGFR targeted therapy as 
higher ST-grades were shown to be associated with a better response to −EGFR therapy [4]. 
This is translated into improved survival (OS, PFS or both) estimated by Kaplan Meier [18].  
Therefore, the identification of a ST predictive biomarker would allow a better adjustment of 
ST-treatment and also prediction of response on targeted −EGFR therapy in mCRC. 
Unfortunately, such a marker has not been established for the clinical practice, yet. 
 
Considering that ST occurs in an organ not related to the primary tumor, and the fact that the 
molecular mechanism driving ST are not fully understood, it is a useful and unbiased strategy 
to search for predictive biomarkers by screening for any type of DNA-polymorphisms (SNPs) 
which are associated with ST. In a second step it might then be helpful to deduce possible 
molecular mechanisms bases on the gene(s) in which the polymorphisms were found to build 
a model for –EGFR related ST. This model can subsequently be tested by translation onto 
clinical cases giving also an explanation why there are variations of ST grade among different 
patients (Table 1). This approach can be done by an unbiased, genome-wide-association-
study, investigating all variations across the whole genome. However, for this approach 
hundreds, better thousands of individuals are required [19, 20]. As it is difficult to get hands 
on such huge numbers of identically treated patients, thus from a clinical study, to exclude co-
confounders as much as possible, a targeted approach is a reasonable alternative. For this 
approach, analysis of selected DNA-markers is done. Thus, fewer cases are in need for a 
3 ‘Papules and/or pustules covering >30% BSA, which may 
or may not be associated with symptoms of pruritus or 
tenderness; limiting self-care ADL; associated with local 
superinfection with oral antibiotics indicated’ 
Temporal 
interruption of 
therapy and 
systemic treatment 
4 ‘Papules and/or pustules covering any BSA%, which may 
or may not be associated with symptoms of pruritus or 
tenderness and are associated with extensive superinfection 
with IV antibiotics indicated; life- threatening consequences 
End of therapy, 
systemic treatment 
5 ‘Death’ - 
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robust analysis but the difficulty clearly lies in the selection process of appropriate DNA 
polymorphisms or genes as biomarkers, which are putatively important. From a point of 
biomedical reasoning it can be assumed that such biomarkers should be related to molecular 
mechanisms of ST. 
 
1.3 Putative mechanisms of skin toxicity include skin-environment, immune 
regulation and immune-cell receptors 
Several theories on the molecular mechanisms underlying ST have been postulated. [21] As 
ST occurs in the skin, skin-related effects have to be taken into account: EGFR is expressed in 
basal keratinocytes [22] and its inhibition causes apoptosis of keratinocytes [23]. Therefore, 
one possible explanation for the occurrence of ST might be a higher susceptibility for EGFR-
inhibition of the skin-environment. This effect may be related to changes in the EGFR as well 
as EGFR-independent mechanisms. 
Another mechanism is related to the immune system: As a part of their mechanism of action, 
immune cells bind therapeutic antibodies like -EGFR-antibodies at their Fc-region by Fc  
receptors (FCRG). With their antigen specific part these antibodies make contact with high 
level EGFR expressing tumor cells thus bringing together the immune- and tumor cells. In 
case the immune cells have cytotoxic potential, like NK (natural killer) cells, the connected 
cell, for example the tumor cell, will die. Thus, this process has been termed antibody-
dependent-cellular-cytotoxicity (ADCC) [24]. This mechanism might help to explain 
variances in the severity or grade of ST, which might depend on differences in immune cell 
regulation and involved immune receptors. 
 
1.4 DNA polymorphisms associated with acne, SLE and Fc receptor  (FcRγ) are 
promising biomarkers of skin toxicity 
In a next step, potential DNA polymorphisms related to the possible pathogenic mechanisms 
mentioned have to be selected. Assuming that ST is a tumor independent effect, selection of 
non-oncological model diseases, which match the putative mechanisms, can be one promising 
approach: 
o First, a common disease linked to deregulation and changes in the skin environment is 
acne [25] which shares many characteristics with ST, which often presents as acneiform 
rash. Several SNPs altering susceptibility to acne have been identified [26, 27].  
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o Second, systemic lupus erythematosus (SLE) is linked to immune dysregulation 
including skin effects. Several SNPs were found to be associated with SLE [28, 29]. As 
the skin-related manifestations [30] and part of the pathogenesis in SLE patients might 
involve severely deregulated immune cells [31], polymorphisms associated with SLE 
may be used as predictors for ST. In addition, Fc-receptor polymorphisms are also 
associated with SLE [32]. 
o Third, SNPs in the family of immunoglobulin receptors (Fc receptors, fragment 
crystallizable) which bind the therapeutic -EGFR antibodies may also influence the 
affinity of the antibody. On the other side, SNPs in the EGFR and its pathways have been 
described in the context of ST already without identification of clinically used 
polymorphisms [33, 34]. However, SNPs in Fc-Receptors may vary the intensity of the 
immune system related effect ADCC. Given CET is an IgG1-antibody [35], it binds to 
Fc- receptors (FcRγ) [36]. In particular, a polymorphism in the FCGR3A gene has been 
shown to influence the IgG-binding capacity of Fc-receptors [37]. To investigate possible 
effects of Fc-Receptor polymorphisms, common polymorphisms in genes encoding Fc-
-receptors (FcRγ: FCGR2A, FGR2B, FCGR3A, FCGR3B) might be promising targets. 
Fig. 1: Groups of promising biomarkers for ST. EGFR downstream and upstream targets were included: Immune cell 
associated targets known to be associated to systemic lupus erythematosus (SLE), Fc-receptor (fragment crystallizable) 
polymorphisms and skin environment associated polymorphisms known to be associated with acne were selected based on 
literature.  
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For the measurement of several distinct SNPs in different parts of the genome, a targeted 
next-generation-sequencing (NGS) including bioinformatic evaluation is the standard-
approach. 
2. Material and Methods 
2.1 Metastatic Colorectal Cancer patients treated with Cetuximab from 
randomized phase 3 study 
Stage IV mCRC patients (age between 18 and 75 years) treated with the α-EGFR monoclonal 
antibody Cetuximab were selected from the FIRE-3 study, which was an open-label 
randomized phase 3 study including stage IV histologically confirmed mCRC comparing a 
FOLFIRI CTX backbone together with either CET or bevacizumab (BEV) [13]. As part of the 
study the parameters gender, age, ECOG performance status, ORR, survival and Skin Rash 
grade (CTCAE 4.0) were collected besides others. 
For this study two subgroups were selected from the FOLFIRI, CET (n=380) study arm: 
1. the training set (n=16) consisting of ST grade 1 and 3 patients and  
2. the validation set (n=55) consisting of ST grade 1, 2 and 3 patients. Patients with and 
without RAS and BRAF mutations were included. 
Probes and clinical data were procured by Prof. Dr. Sebastian Stintzing and Prof. Dr. Volker 
Heinemann. 
 
2.2 DNA preparation and isolation 
The analysis aimed for genomic alterations, namely individual SNPs of the patient genomic 
DNA was applicable for this study. Therefore, DNA was isolated from peripheral blood 
mononuclear cells (PBMNC) by spinning down (10min, 1600xg, room temperature) 5ml of 
patient’s blood taking the buffy coat. This was washed two times in phosphate buffered saline 
(PBS). Subsequently, the sediment was dissolved in lysis buffer of QIAGEN’s blood DNA 
kits. Finally, DNA was isolated following the instructions given in the manual of the vendor 
resulting in high quality DNA. 
Then the concentration of the DNA containing solution was measured employing UV-
photometry determining the optical densities at =260nm (OD260), =280nm (OD280), and 
=320nm (OD320). 
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2.3 Targeted Next-Generation-Sequencing using Custom Panels in Ion Torrent 
PGM 
Primer design was done employing Thermo Fisher’s Ion Torrent AmpliSeq™ Custom Panel 
Designer [38] resulting in three Ion AmpliSeq™ Custom DNA Hotspot Panels (Table 2). 
 
Panel Targets Coverage 
Number of 
Amplicons 
Pipeline 
Version 
Solution 
Type 
DNA 
Type 
Application 
type 
Acne 14 100% 12 4.0 
High 
Specificity 
Standard 
DNA 
germline 
SLE 36 100% 35 4.0 
High 
Specificity 
Standard 
DNA 
germline 
FcRγ 20 100% 20 3.6 
High 
Specificity 
Standard 
DNA 
germline 
Table 2: Custom Panel generation. Input parameters utilized for automated generation of primer panels using Ion Torrent 
AmpliSeq™ Custom Panel Designer (Thermo Fisher) [38]. 
For generation of libraries, DNA quality was checked in a first set of steps. On the one hand, 
the DNA concentration was measured using the Qubit-system (Thermo Fisher, 𝑐𝑜𝑛𝑐𝑄)  
following the user’s manual. Additionally, the quality of the DNA was determined by running 
a quantitative (q)-PCR using the patient’s DNA together with a detection system specific for 
the RNase P-gene (Roche Diagnostics). The concentration of amplifiable DNA was calculated 
on the basis of a standard curve (𝑐𝑜𝑛𝑐𝑅𝑁𝑎𝑠𝑒𝑃). Subsequently, the ratio of both concentration 
values was calculated (
𝑐𝑜𝑛𝑐𝑄
𝑐𝑜𝑛𝑐𝑅𝑁𝑎𝑠𝑒𝑃
). DNAs with a ratio above the factor 2 were not used but 
instead DNA was re-purified again as inhibitory factors were left over like iron-ions from the 
heme of the lysed erythrocytes or others. This tedious work was done to save costs in the 
following expensive library generation step. 
Libraries were made using 10ng of DNA based on 𝑐𝑜𝑛𝑐𝑅𝑁𝑎𝑠𝑒𝑃 together with Ion AmpliSeq™ 
Library Kit 2.0 in 21 PCR-cycles following the instructions given in the manufacturer’s 
protocol. Subsequently barcodes (Ion Xpress™ Barcode Adapters) were added by the FuPa 
reaction in the Ion AmpliSeq™ Library Kit protocol to assort for the analysis of data the 
sequences to individual patients indexed by their individual barcode. After this step, libraries 
were ready for clonal amplification. Therefore, comparable amounts of the libraries should be 
put together to reach comparable coverage rates. Thus, another concentration determination 
was run using the qPCR system Quantitizer (Thermo Fisher) following the user’s manual. 
Each 30pmol of 16 libraries (patients) were put together into a total volume of 70µl which 
was transferred into the Ion Chef™ pipetting station (Thermo Fisher) together with Ion 
PGM™ IC-200 Supplies and Ion 318™ Chips v2 BC based on the protocol of the Ion PGM™ 
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IC-200 Kit. The Ion PGM™ IC 200 Kit components include template reagents, nucleotides, 
enzyme mixes, spike-in sequencing controls, buffers & solutions, consumables, and supplies. 
In the Ion Chef™ a clonal amplification of individual library molecules was done by 
emulsion PCR (emPCR) on solid phase represented by primer labeled beads. After this 
amplification step the Ion Chef™ separated DNA carrying from empty beads and loaded them 
together with sequencing-primers and Taq-Polymerase onto IonChips-316™ which were now 
ready to be loaded into the Ion Torrent PGM™ (Personal Genome Machine, Thermo Fisher). 
For each run on the Ion Torrent PGM™ a run protocol was written linking the patient’s ID 
with the barcode used. Wash buffers, sodium hydroxide and nucleotides were mounted on the 
Ion Torrent PGM™. Next a test IonChip-316™ was mounted on the PGM and a pre-run was 
launched to allow the setting of a neutral pH value of the wash buffer and to get rid of air 
bubbles in the tubes. After this step the test chip was exchanged with a library/ primer/ DNA-
polymerase loaded IonChip-316™ and the run was finally started. 
 
Wet-lab work was carried out and thereby raw-data generated by members of the Jung Lab, 
especially Gertrud Lenz. 
 
2.4 Quality control and mapping using Ion Reporter 
Sequencing results were aligned to the human reference genome built hg19 thereby 
generating BAM (binary alignment metafiles), which were transferred from the Ion Torrent 
PGM™ on the local Ion Server System™. With the help of the Ion Torrent Suite™ software 
BAM files were transferred into the Thermo cloud. This transfer was done by SSL encryption 
and using the anonymous run names for the cases to protect patient’s subgenomic genetic 
data.  
For fine analysis of the data the Ion Reporter™ platform (Version 4.6) was used. In a first 
step, the reads created by the sequencer had to be aligned to the human reference genome in a 
mapping process. hg19 built of the human genome was used for subsequent steps. The 
mapping was carried out on Ion Reporter™ platform utilizing the optimized settings for Ion 
Torrent PGM™ data. 
 
2.5 Variant Calling and Filtering using Ion Reporter 
The information on the status of the target variants had to be determined from the aligned read 
in the BAM file in a process called variant calling. Ensured by the design of the sequencing 
process, most variants were covered by several sequencing reads for each patient. Given this 
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information, the putative status of the variant (reference or non-reference) and statistical 
errors were determined employing bioinformatics: 
Variants were called applying a workflow generated in the Ion Reporter™ including 
annotation of dbSNP138 based on the genome built hg19 [39]. Hotspot region files matching 
the sequencing targets were included to enhance calling of reference-SNPs of interest. Filter 
criteria were set for germline variant detection including minimum SNP variant score of 10.0, 
minimum SNP allele frequency of 0.1 and minimum SNP coverage 10. These filter settings 
ensured the necessary sensitivity to detect the variants while limiting false-positive calls to a 
minimal level. 
 
2.6 Variant data processing 
Variant call-results were exported as data-files in the VCF (variant call format) and TSV (tab 
separated values) formats and appended in the spreadsheet program Microsoft Excel® version 
15. The resulting file allowed determining the number of successful variant calls per panel 
and patient serving as a quality measure for the panels including information from all patients. 
As the data sets should be analyzed by the software package PLINK [40], which allowed 
variant association studies by linkage analysis sequencing calls and ST phenotypes, they had 
to be reformatted to match PED and MAP format specifications of PLINK. [40] 
Caused by unpredictable biological properties of the sequencing process, sequencing quality 
varies between variants in the process. These result in varying performance of the variant 
calling process. The proportion of missing genotypes (
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑠𝑠𝑖𝑛𝑔 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑠𝑆𝑁𝑃
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠𝑆𝑁𝑃
) allows 
an estimation of sequencing quality of each variant in the patient groups. To obtain this 
estimation, the ‘--missing’ algorithm of PLINK version 1.07 (v1.07) [40] was applied to 
calculate the number and proportion of missing genotypes per SNP. Results were visualized 
using Haploview version 4.2 software’s plotting functionality. [41] 
 
2.7 Analysis for Deviations from Hardy-Weinberg Equilibrium using PLINK 
As a biology-based indicator of consistency, deviations from Hardy-Weinberg-Equilibrium 
[42] were calculated using the exact Hardy-Weinberg test [43] statistic function of PLINK 
v1.07 using p=0.001 as threshold. Gender information was not included into the analysis. 
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2.8 Genotype-Phenotype association analysis using PLINK 
The quality-tested results from sequencing representing the genotype information of each 
patient had to be analyzed with respect to the phenotype information – represented in ST 
levels. This kind of analysis of the association of phenotypes with genotypes is known as 
‘association analysis’ and is based on regression models. Genotype phenotype association 
analyses for quantitative markers [44] were performed using PLINK v.1.07. p-values were 
calculated using Wald statistic [45]. Individuals with no gender information were included 
into the analysis. Again results were visualized using the plotting functionality of Haploview 
version 4.2 [41]. 
 
2.9 Linkage analysis using Haploview 
Variants determined in the association analysis were tested for genetic association with other 
variants in a process called ‘linkage analysis’. It gives information if the variants found are 
likely to be causal for the genotype-phenotype association found or may be bystanders. 
Groups of associated variants – called Haplotypes – were analyzed using Haploview v4.2 [41] 
with block definitions from Gabriel et al. [46]. Linkage Disequilibrium (LD) data was 
obtained from Hapmap database utilizing the Haploview download function. 
 
2.10 Survival Analysis based on Kaplan Meier estimators 
Survival of patient groups was calculated using the Kaplan Meier model [18] in SPSS 
Statistics version 24. p-values pooled over strata were calculated using the Log-Rank test 
[47]. Results were visualized using survival diagrams. 
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3. Results 
3.1 Skin toxicity was significantly associated with survival in the FIRE-3 study 
First of all, it was tested if there was an association between the ST status and survival in our 
sub-collection of the FIRE-3 study applying the Kaplan Meier model because this correlation 
had been described before [4], thus indicating the validity of the FIRE-3 study as well as that 
these cases were suitable to investigate the hypothesis. As a training-validation approach was 
aimed for, the two randomly chosen sub-groups of training set and validation set both were 
tested independently of each other. A statistically significant association between ST status 
and survival for both subgroups was demonstrated for both PFS (ptraining set=0.016,  
pvalidation set=0.004) and OS (ptraining set=0.059, pvalidation set<0.001) (Fig. 2). As these results 
clearly reflected published data this support was taken to support the idea that the FIRE-3 
subgroup of patients was representative for a ST-patient collective. 
 
Fig. 2: Severity of skin toxicity is associated to progression free survival (PFS) and overall survival (OS). 
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3.2 Patient collective for training-validation-approach selected 
To test the quality of potential biomarkers the statistical training / validation model was used 
as an approach using the following:  
1. The training set consisted exclusively of low (CTCAE 1)- and high (CTCAE 3)- grade 
ST phenotypes. With this high contrast between the two states an increase in the 
sensitivity for genetic association analyses was expected. [44] 
2. The validation set also included intermediate-grade (CTCAE 2) ST phenotypic 
patients as this was a better approximation for collectives of real patients. 
In addition, as significant SNPs from the training set were evaluated in the analysis of the 
validation set, adjustment for multiple testing was not necessary [48]. To ensure 
comparability of patients and data collection within and across both groups, selection of 
patients from one clinical study has major advantages. Therefore, a clinical study with a 
adequate number of metastatic colorectal cancer patients receiving −EGFR therapy was 
employed to obtain patients for both training and validation set. 
To do so, training and validation subgroups were selected from the FIRE-3 study collection 
resulting in 71 patients totally (16 patients in the training set; 55 patients in the validation set). 
These two groups did not match perfectly but were reasonably comparable (Table 3). The 
presented groups were included in the subsequent analyses. 
 
Variable 
Training  
(n=16) 
Validation 
(n=55) 
p 
Age Mean (SD) 64,231 (8.89) 62,418 (9.75)  0.543 
Sex 
  
  
Male 6 (37,50%) 43 (78,18%) 
0.049  Female 7 (43,75%) 12 (21,82%) 
Unknown 3 (18,75%) 0   (0,00%) 
RAS 
  
  
Wild-type 8 (50,00%) 47 (85,45%) 
1.000 Mutated 1   (6,25%) 8 (14,55%)  
Unknown  7 (43,75%) 0   (0,00%) 
Skin  
Toxicity 
Grade 1 11 (68,75%) 19 (34,55%) 
0.017 Grade 2 0   (0,00%) 16 (29,09%) 
Grade 3 5 (31,25%) 20 (36,36%) 
ORR 
  
  
No 7 (43,75%) 11 (20,00%) 
0.007 Yes 3 (18,75%) 40 (72,68%) 
unknown 6 (37,50%) 4   (7,32%) 
 
Table 3: Overview of patients in the training- and validation set. Molecular pathological and clinical data of the patients 
included in the training- and validation sets. p values are based on Chi-Square tests for categorial variables and t test for 
continuous variables. (ORR; overall response rate, RAS; rat sarcoma viral oncogene homolog, SD; standard deviation) 
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3.3 70 Single nucleotide polymorphisms associated to acne, SLE, FcRγ were 
selected for the investigation of skin toxicity 
In parallel, SNPs associated with susceptibility to acne, SLE or FcRγ binding were selected 
based on screening of literature and online databases (Fig. 3). 
 
Fig. 3: SNPs and respective genes selected for targeted sequencing (Additional information: Appendix A.2; FcRγ; Fc 
receptor γ, SNP; single nucleotide polymorphism, SLE; systemic lupus erythematosus). 
14 SNPs associated to acne [26], 20 SNPs associated to FcRγ [39] and 36 SNPs associated to 
SLE [28] were found to be putative biomarkers for ST (Fig. 3). Six of these SNPs were found 
in both the SLE and FcRγ group as well, because the FcR also has a functional role in SLE. 
 
3.4 SNP panel sufficiently covered by Custom AmpliSeq Panels 
Next an amplicon panel was generated which covered all previously identified SNPs. 
Therefore, the commercially available AmpliSeq™ Custom Panel Designer (Ion Torrent) was 
employed. [38] As some of the SNPs were located on a single amplicon unit the number of 
amplicons was consequently smaller than that of the SNPs. It was possible to cover all SNPs 
with three individual panels (Table 4).  
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Panel No of SNPs % covered in panel No of amplicons AmpliSeqTM version 
acne  14/14 100% 12 4.0 
SLE  36/36 100% 35 4.0 
FcRγ  20/20 100% 20 3.6 
Table 4: Coverage of targets for sequencing in constructed primer panels (Full list refer to: Appendix A.1) 
 
3.5 Coverage of SNPs by the panels is adequate 
Having created panels covering the SNP-targets, sequencing of all patients was performed 
using the Ion Torrent PGM platform. To obtain the variant information for each case, a 
bioinformatics pipeline was applied to the resulting data: 
1. First, absolute genomic positions of raw data reads from the Ion Torrent PGM™ 
Sequencer had to be identified. This mapping was done integrating the Ion Reporter™ 
Software (version 4.6). Low quality reads, which could not be mapped to the reference 
hg19, were dropped out. 
2. Second, from all reads mapped to each target region, the respective variant had to be 
identified by variant calling. As SNPs are germline variants, fewer reads and thus 
coverage for each analyzed region were necessary to call the variant compared to 
when analyzing tumorgenetic mutations from heterogeneous probes like tumors. 
Variant calling was also done with help of run by the Ion Reporter Software (version 
4.6) including BED-files containing the target regions. During this step, preferences 
for germline variants and quality filters based on coverage, minimum allele 
frequencies and p-value-based scores were applied. 
This procedure resulted in the identification of genotypes for each variant and patient 
provided that reads in sufficient quality were available. 
 
In a next step, this variant information was used to get an overview of the performance of 
sequencing for each SNP with regard to the whole patient group. This allowed an estimation 
of the quality of the panels which was determined by measuring the share of missing 
genotypes for each SNP:  
𝑀𝑖𝑠𝑠𝑖𝑛𝑔 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑠 (%) =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑠𝑠𝑖𝑛𝑔 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑠𝑆𝑁𝑃
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠
 
The results for non-missing variants of each of the SNPs (colored points) were visualized 
using the Haploview software (Fig. 4). [41]  
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Fig. 4: Proportion of missing genotypes for each SNP – shows the coverage of the individual sequencing targets. A low 
proportion shows that the respective variant was called in the majority of patients (Full list Appendix A.3) 
In conclusion, all but two SNPs showed at least one called genotype (Fig. 4). Furthermore, the 
majority of SNPs showed a coverage of more than 50%. This resembled a satisfactory 
coverage and was reached by the majority of SNPs included in the panels. A low genotyping 
rate is taken into account by the following analyses. Therefore, SNPs with few calls were not 
excluded from further analyses. Furthermore, some SNPs not targeted in the first place were 
also sequenced and identified by the variant calling algorithms, because of their close location 
to the panels’ original targets. These variants were included into all further analyses leading to 
a higher total number of variants. 
 
3.6 Homogeneous, high sequencing quality for DNA probes 
Another quality aspect beside the quality of the whole panel, which represents a combined 
quality measure value, is the sequencing quality of each individual DNA probe, which was 
checked for in a subsequent step. For this task the number of successfully sequenced 
genotypes for each patient was investigated (Fig. 5).  
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Fig. 5: Number of variants called per patient – shows the completeness of variant calls per patient. For the majority of 
patients, the panels show an appropriate number of present genotypes (Overview table in Appendix A.3) 
To conclude, the majority of patients was analyzed with a good to at least sufficient coverage 
for all panels. Therefore, this set of data could be utilized for further analyses. In total, variant 
calls were available for for 61 patients. 
 
3.7 Only a single marker, rs1674761, showed a significant deviation from Hardy-
Weinberg equilibrium indicating a systematic error 
The quality checks performed up to now only considered the technical quality of the data but 
did not consider possible systematic errors like population stratification or genotyping errors. 
As these systematic errors often lead to artificial deviations from the Hardy-Weinberg-
equilibrium (HWE) and, as a result, false positive results. Based on a HWE model, these 
potential false positive results can be detected [19]. For this issue the PLINK software, which 
allowed a linkage analysis of the different SNPs, was employed. A strict exclusion level was 
chosen in that the p-value had to be lower than 0.001. Only a single marker (rs1674761, 
FcRγ-panel, FCGR2B gene) was found to deviate significantly from HWE (p<0.001). 
Thus, after this final step of quality control a set of 68 SNPs and 61 patients remained for the 
further functional analysis to figure out association or linkage of SNPs with ST. 
 
3.8 rs849142 significantly associated with Skin Toxicity 
To investigate a potential association between SNPs and ST, the genetic association analysis 
routine of PLINK was employed now. Therefore, an association between genotypes (SNPs) 
and severity of ST for each patient group was calculated. Here, SNPs showing more than two 
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alleles were excluded from the analysis, as they cannot be evaluated in a typical quantitative 
genetic association analysis. 
For quantitative traits like ST, regression models including the phenotype as dependent 
variable and genotype – coded as number of non-reference alleles – as explanatory variable 
allowed an evaluation of interdependence of genotype and phenotype. This so-called 
quantitative association analysis could be performed for multiple SNPs using PLINK (v. 1.07, 
[40]). The results of this analysis were visualized in Manhattan plots again using Haploview 
[41]. These plot associated p values for each SNP. Significance levels were visualized as blue 
(p=0.05) or red (p=0.01) lines. Data points above the respective blue and red lines indicated 
SNPs which were significantly associated with ST on the given respective significance levels 
(Fig. 6: training set; Fig. 7: validation set; Fig. 8: whole data set). 
 
Fig. 6: Manhattan plot for association of SNPs with ST in Training Set: rs849142 shows a significant (p=0.00395) 
association to ST. The position over the red line indicates a higher significance level than p=0.01. All other SNPs positioned 
below the blue line are associated with a significance of weakter than p=0.05. (Full list Appendix Table A.4) 
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Fig. 7: Manhattan plot for association of SNPs with ST in Validation set: rs849142 and rs463426 show a significant 
(p<0.05) association to ST. Therefore, they are shown above the blue line. All other SNPs are insignificant on p=0.05, 
represented by their position below the blue line. (Full list Appendix Table A.4) 
 
 
Fig. 8: Manhattan plot for association of SNPs with ST in Both Groups: rs849142 and rs463426 remain significant on 
p=0.05 when analyzing both groups together. No additional SNPs appear as significant. (Full list Appendix Table A.4) 
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The SNP rs849142 T allele compared to C allele was significantly associated with ST in the 
training set (p=0.00395, Fig. 6). This result could be confirmed in the validation set 
(p=0.04362, Fig. 7) though the p value in the validation set showed a less clear significance. 
This phenomenon is a well-known statistical effect in groups containing intermediate 
phenotypes: As SNPs do often change the probability of a phenotype but do not show a full 
penetrance, in case-control approaches including non-extreme phenotypes they are more 
difficult to unravel statistically [44].  
In contrast the SNP rs463426 was found to be significantly associated to ST in the validation 
and overall groups only. As it failed to reach significance in the training set (p=0.0663) it was 
not included into further analyses. 
 
Taken together, rs849142 turned out to be a potential, validated candidate predictive 
biomarker of ST in metastatic colorectal cancer. In particular, an elevated number of T alleles 
(in contrast to C alleles) was associated with higher ST-grade. Thus, as the major milestone of 
this work, rs849142 genotyping could be used as a personalized estimator for ST-risk in -
EGFR treatment of metastatic colorectal cancer at least when using Cetuximab, what might 
turn out as an advantage for patients and physicians. 
 
3.9 rs849142 is not associated with survival 
As ST is also associated with survival (Fig. 2) [4] and rs849142 predicts ST, it was now 
investigated if SNP rs849142 also correlated with survival and may thus also be a useful 
predictive biomarker for -EGFR targeted therapy complementing RAS mutations. To 
investigate this potential relationship, the Kaplan Meier model together with Overall Log-
Rank-Estimations were applied following the same scheme of training- and validation set as 
described already before (Fig. 9). 
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Fig. 9: Kaplan Meier estimators for survival stratified by rs849142 genotypes. 
In the training set a significant association of rs849142 with survival was found for PFS 
(p=0.005) but not OS (p=0.072). However, no association neither with PFS nor OS were 
confirmed in the validation set (PFS p=0.644, OS p=0.934). Therefore, rs849142 was not 
associated with survival and is thus not an appropriate predictive biomarker for survival in 
anti-EGFR targeted therapy.  
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3.10 Deciphering a functional role for rs849142 using linkage disequilibrium 
In a final approach it was investigated if the genomic context of rs849142 is associated to 
specific genes which might help to model to understand the molecular mechanism underlying 
ST or at least the association of rs849142 and ST. DNA fragments located next to each other 
are often inherited together as they build up a coupling group except in cases a breakage-point 
is located between them. Thus, SNPs especially close to each other often show a highly 
positive correlation in their co-occurrence. This is referred to as linkage disequilibrium. Even 
in cases where linkage disequilibrium is found between two loci on then DNA like a SNP and 
a gene it is difficult to differentiate between causal and bystander effects (Fig. 10) [49]. 
Nevertheless, such an approach is at least worth to be tried. Therefore, two approaches where 
used here: 
1. Is rs849142 located in a gene and is this gene known to be associated with ST or ST-
like effects?  
2. Might other genes flanking rs849142 on the same coupling group be responsible for 
ST or ST-like effects? 
 
Fig. 10: Biology of a haplotype: rs849142 may be associated with another causal SNP and therefore only indirectly 
associated to skin toxicity. Adopted from Balding 2006 [49]  
 
3.11 rs849142 is located in the JAZF1 gene 
rs849142 is located on chromosome 7 (position 28146272 in GRCh38) which is part of the 
intronic region of the JAZF1 gene (Juxtaposed with another zinc finger protein 1 gene) also 
known as TIP27 (27 kDa protein TAK1-interacting protein), a repressor of transcriptional 
activation by TAK1 [5]. TAK1 was shown to influence glucose homeostasis related to PI3-
Kinase/AKT in mice [6] and lipid metabolism in adipocytes [50]. Thus, this gene does not 
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seem to have obvious effects in ST. To investigate the importance in ST-related tissues, the 
mRNA expression profile of JAZF1 was recovered from the GTEx-portal 
(http://www.gtexportal.org) and was subsequently analyzed (Fig. 11). The highest expression 
profiles for JAZF1 are found in whole blood followed by sigmoid colon and also relatively 
high expression in adipose tissue but less prominent in the skin. 
 
Fig. 11: Expression of JAZF1 gene in several normal tissues: JAZF1 is expressed in blood, colon and skin as well 
(GTEx Analysis Release V6 (dbGaP Accession phs000424.v6.p1); http://www.gtexportal.org/). Estimated in ‘Reads Per 
Kilobase of transcript per Million mapped reads’. 
 
3.12 rs849142 shows linkage disequilibrium with other SNPs but not other 
genes 
Thus, in a next step the linkage disequilibrium rs849142 was analyzed by linkage analysis of 
SNPs neighboring rs849142 employing the Haploview software again [41]. Genomic variants 
near each other tend to be statistically associated (Fig. 10): New variants occur in the context 
of preexisting other variants – referred to as haplotype. Therefore, the new variants are 
associated to variants in the respective haplotype. This is described as variants being in 
linkage disequilibrium (LD) within the population. As long as no recombination or new 
mutation occurs, the variant remains associated to the Haplotype. These variants can be 
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pooled in haplotype blocks using linkage disequilibrium measures*. Thus, variants 100 
kilobases up- and downstream of rs849142 were analyzed for LD and haplotype blocks.  
Linkage analysis revealed several SNPs within in linkage disequilibrium with rs849142 which 
were visualized in LD- (linkage disequilibrium) plots (Fig. 12). Importantly, only smaller 
blocks (coupling groups) were found (Fig. 13). 
rs849142 was found in a block together with the two other SNPs rs864745 and rs849140, 
respectively (Fig.13). However, rs849142 was also in high LD with several other SNPs (Fig. 
12). 
Therefore, the differentiation between a causal and a bystander effects of rs849142 remained 
unclear. But such a differentiation of markers is irrelevant for clinical purposes: A non-causal 
marker in linkage disequilibrium with a causal marker would also serve as a surrogate 
measurement. 
 
Fig. 12: Linkage Disequilibrium Plot of SNPs in JAZF1 gene using Version 2 release 24 CEU (CEPH, Utah residents 
with ancestry from northern and western Europe), chromosome 7 28152+/-100 kilobases: Variants are represented by 
grey lines on top. As an overview it shows that many SNPs form groups, which are in linkage equilibrium with each other, 
represented by red triangles under the respective variants. Coupling groups based on Gabriel Block definition are encircled 
by black triangles. rs849142 is indicated by a blue arrow (detailed view: Fig. 13, 14; full-size figure: Appendix A.5) 
                                                 
* Haplotype blocks are regions with little evidence of historical recombination. Gabriel et al. 
(2008) define them as ‘as a region over which a very small proportion (<5%) of comparisons 
among informative SNP pairs show strong evidence of historical recombination’ 
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Fig. 13: rs849142 Haplogroup: Each rectangle represents LD between two SNPs; red indicates a strong LD. 
Rectangles indicating LD values for rs849142 are indicated by arrows: Many SNPs are in LD with rs849142. Using the 
block definition from Gabriel et al. [46], two other SNPs rs864745 as well as rs849140 form a coupling group with rs841942: 
(Fig. 14).  
 
 
 
Fig. 14: Block definition from Gabriel et al [46] 
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4. Discussion 
4.1 rs849142 might be a validated biomarker predicting ST in mCRC which may 
improve patients’ treatment 
Aim of this research project was to find a predictive marker for skin toxicity in targeted α-
EGFR treatment of mCRC. Besides skin or receptor-specific mechanisms, immune 
dysregulation was proposed as a potential mechanism of  ST.  
This research project discovered the rs849142 SNP T allele as a validated biomarker for skin-
related adverse effects in targeted α-EGFR treatment of mCRC. rs849142 is a common SNP 
in caucasian populations [39] which is known to be associated with SLE [8], lupus nephritis 
[9, 51], or prostate cancer [7]. rs849142 is located in the JAZF1 gene which functions as a 
repressor of transcriptional activation by TAK1 [5] and has an important role in lipid and 
glucose metabolism. [6, 50] Interestingly, the gene JAZF1 was shown to have a high mRNA 
expression in blood – a hint for its role in immune cells. However, expression within the skin 
was found to be low. This was taken as an indicator that the function of JAZF1 might not take 
over a mechanistic role in ST. But it has to be considered that no expression data from skin 
samples with ST is yet available. JAZF1 might be expressed in the skin of patients developing 
ST in the presence of -EGFR directed antibodies like Cetuximab. Moreover, it might also be 
considered that JAZF1 is expressed only in a certain subset of cells like stem cells which are 
in a minority thus explaining overall low expression levels. 
From a biological point of view, these findings suggest that immune cell regulation is an 
important mechanism of ST.  
 
Irrespective of its biological function, rs849142 might be utilized among other markers in 
clinical practice as predictor of ST. In this context, the reliable prediction of ST using 
rs849142 would be a major advantage for both patients and physicians:  
1) On the one hand, patients at risk of high-grade ST may be treated preventively for the 
adverse effect. This might increase quality of life as well as acceptance of treatment. 
In case a preventive treatment is not applicable to the patient, a different treatment like 
anti-VEGF antibodies might be chosen in order to prevent severe adverse events. 
2) On the other hand, the use of preventive agents for ST might be limited to the cases 
where necessary: Patients in which the biomarker predicts a lower risk of ST could 
skip the treatment for ST. The agents used for prevention ofr ST, e.g. glucocorticoids, 
retinoids and antibiotics, might cause severe adverse events or might interfere with the 
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biological function in an unknown manner. Therefore, apart from economic reasons, 
their use should be limited to cases where necessary for medical reasons. 
Yet, there are some obstacles for broad adoption of rs849142 as a predictive marker for ST: 
1) Surely, the occurrence of adverse events is not solely dependent on genetics: 
Additional factors like performance status or age may also play a major role. A 
possible way to take them also into account would be a rating system based on genetic 
as well as clinical factors. 
2) Additionally, for treatment of stage IV cancer patients, subjective and personal aspects 
should be considered. In this scenario, genetic tests might be of supportive value in the 
final decision of treatment. 
 
To review the value of rs849142 in a clinical setting and to gain further information on its 
reliability, in a next step, it should be tested in a prospective clinical study.  
 
Given that ST has been shown to be associated with survival of mCRC patients treated with 
-EGFR antibodies, a predictive biomarker for ST might also predict response and survival of 
mCRC patients. As ST occurs after treatment start, rs849142 may be a predictive biomarker 
and allow better treatment planning. In contrast, ST itself is retrospective and is only a 
prognostic but not predictive marker.  
The training set showed some association 
of rs849142 to survival (PFS p=0.005; OS 
p=0.072). The high-grade-ST-associated T 
allele is associated with longer survival, 
which is in line with theoretical 
assumptions. However, this association 
could not be confirmed in the validation 
set. 
One explanation is lack of statistical power: 
On the one hand, rs849142 and ST did not 
show a perfect association. On the other 
hand, ST is only one of several potential predictors for survival (Fig. 15). Therefore, the 
association from a ST-specific marker to ST-related changes in survival may be influenced by 
several additional variables including patient-specific characteristics. Subsequently, these 
Fig. 15: Lack of association between rs849142 and survival 
may be due to insufficient statistical power 
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confounders might make the association to survival difficult to unravel. Therefore, more 
patients may be necessary to show a significant effect on survival.  
Alternatively, this lack of association to survival can have biological reasons: rs849142 might 
only reflect ST-specific aspects, as it has been selected with focus on ST, and not on response. 
To find predictive markers for response, other selection processes and therefore other SNPs 
may be necessary. It further points on the importance of molecular genetic analyses specific 
for adverse events. 
 
4.2 Limitations of this work 
As this work has focused on a predefined set of SNPs, it does not provide a comprehensive 
overview like genome wide association studies (GWAS) does. Yet, the theoretical foundation 
of SNP selection and the training-validation approach give a certain validity to the results. 
Statistical adjustments of multiple testing were not applied, because a validation set was 
included and only used to validate results from the training set. As a consequence, SNPs 
significantly associated to ST in the validation but not in the training set were not further 
investigated. Due to the limited number of tested markers, multi-marker analyses were 
difficult to carry out, too. Use of the DNA sequencing methods in the training as well as the 
validation set might yield some problems, but systematic errors for sequencing within high or 
low ST groups seem unlikely, because sequencing quality strongly depends on the DNA 
quality. Systematic differences of DNA quality between high and low ST groups seem 
unlikely. 
Additionally, given that the analysis was carried out in a non-randomized, retrospective 
approach selection effects with regard to other variables than ST cannot be ruled out fully. For 
this reason, a prospective clinical trial using rs849142 as a predictor for ST would be the next 
step before application to clinical practice. 
Yet, clinical application of a single genomic marker like rs849142 may have structural 
weaknesses: rs849142 is no exception concerning the fact that the predictive value of SNPs is 
often limited to probabilities [19]. Therefore, deterministic predictions for individual patients 
remain difficult. This limitation may lead to false positive as well as false negative predictions 
by the biomarker. In fact, this could harm patients. In order to estimate this risk, calculations 
on positive and negative predictive value in a prospective clinical trial would allow physicians 
better judgments on the value of rs849142 in this setting. An additional way to increase the 
predictive value would be the multi-marker approach mentioned above. 
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In addition, the approach to identify markers associated to both ST and response is 
problematic. Biological mechanisms leading to response to α-EGFR-antibodies are not 
necessarily the same as those mechanisms which cause ST. Targets for sequencing were 
selected on the basis of putative ST-related mechanisms, but without taking mechanisms for 
response and survival into account. This may be one reason why this work was able to find a 
SNP associated to ST but not to survival. Therefore, studies to find predictive markers for 
mCRC patients treated with α-EGFR-antibodies should be based on other sequencing panels 
than those focused on adverse events. 
 
4.3 Further research on the genetic foundation of -EGFR-associated ST should 
be have a broader focus than EGFR and downstream pathways 
Research on molecular mechanisms in targeted -EGFR treatment have been focused on 
EGFR and downstream targets like KRAS or NRAS, as these have a major importance for 
survival and response [52]. This has resulted in some success. SNPs associated with α-EGFR 
efficacy have been revealed in the EGFR [33]. The EGFR pathway [33] and EGFR-turnover 
[53] are also associated with α-EGFR efficacy. Additional targets involving the immune 
system like Fcγ-receptors [54] have also been shown to be associated with α-EGFR efficacy. 
Research on SNPs as predictors for adverse skin effects, has focused on the same targets. Few 
SNPs associated to both survival and ST have been unveiled yet [33]. 
 
Starting from theoretical concept, this work also tested an EGFR-independent approach: 
Immune cell regulation, immune receptors and skin-specific aspects were identified as 
important theoretical concepts explaining the occurrence of ST. Consequently, it was focused 
on upstream targets like Fc-receptors, skin and immune regulation related targets. Thus, this 
work provides a new view on potential markers for ST. The successful identification of 
rs849142 based on a relatively small number of target SNPs shows the high potential of this 
approach. Therefore, future research on the genetic foundation of ST should take 
immunological and skin-related mechanisms into account. 
To further investigate the biological properties of rs849142 in the context of ST, ST-affected 
skin probes will be necessary. Yet, such specimens are not collected routinely and are very 
difficult to obtain. Analyses based on cell-models are also challenging, because a systemic 
condition like ST cannot be modeled in wet-lab conditions easily due to the complexity of the 
system. 
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4.4 Outlook 
rs849142 is a validated predictive marker for ST in α-EGFR mCRC treatment. It shows the 
importance of genetic variations for practical clinical treatment. However, translation of 
research results into clinical practice remains a major obstacle. The broad availability of next 
generation sequencing technology might make genetic analyses more common and increase 
their utilization to estimate response and adverse events. Particularly broader application of 
whole genome sequencing approaches may allow identification of further markers by genome 
wide association analyses. A problem in association studies with SNPs is their partly weak 
association to phenotypes. Therefore, large patient collectives are necessary to reach 
significance. Consequently, recruiting a sufficient number of patients – especially for rare 
diseases or not often used treatments – may be only possible in concentrated clinical centers.  
Given that costs per base sequenced are declining rapidly, further studies should include SNPs 
to gain a more comprehensive overview on the topic. However, this will require a large 
number of patients and careful adjustments for multiple testing. A genome-wide association 
study should also allow the selection of additional SNPs for a screening panel to improve 
reliability and predictive value for individual patients under treatment –EGFR for mCRC. 
 
The results of this work were partly published in a peer-reviewed journal by the author after 
first submission of this thesis [55]. 
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A. Appendix 
A.1 Sequencing targets 
panel type rs-code Chr start end gene 
acne SNP rs5743708 4 154626316 154626317 TLR2 
acne SNP rs4986790 9 120475301 120475302 TLR4 
acne SNP rs4986791 9 120475601 120475602 TLR4 
acne SNP rs361525 6 31543100 31543101 TNFA 
acne SNP rs1800629 6 31543030 31543031 TNFA 
acne SNP rs1799724 6 31542481 31542482 TNFA 
acne SNP rs1800630 6 31542475 31542476 TNFA 
acne SNP rs1799964 6 31542307 31542308 TNFA 
acne SNP rs17561 2 113537222 113537223 IL-1A 
acne SNP rs1048943 15 75012984 75012985 CYP1A1 
acne SNP rs4646903 15 75011640 75011641 CYP1A1 
acne SNP rs743572 10 104597151 104597152 CYP17 
acne SNP rs4133274 8 128676130 128676131 Chr 8q24 
acne SNP rs13248513 8 128691211 128691212 Chr 8q24 
SLE SNP rs9888739 16 31313252 31313253 ITGAM 
SLE SNP rs548234 6 106568033 106568034 - 
SLE SNP rs2230926 6 138196065 138196066 TNFAIP3 
SLE SNP rs7708392 5 150457484 150457485 TNIP1 
SLE SNP rs463426 22 21809184 21809185 - 
SLE SNP rs6590330 11 128311058 128311059 - 
SLE SNP rs4917014 7 50305862 50305863 - 
SLE SNP rs507230 11 35129171 35129172 - 
SLE SNP rs10516487 4 102751075 102751076 BANK1 
SLE SNP rs7812879 8 11340180 11340181 - 
SLE SNP rs7829816 8 56849385 56849386 LYN 
SLE SNP rs13385731 2 33701889 33701890 RASGRP3 
SLE SNP rs10911363 1 183549756 183549757 NCF2 
SLE SNP rs7574865 2 191964632 191964633 STAT4 
SLE SNP rs2476601 1 114377567 114377568 AP4B1-AS1, PTPN22 
SLE SNP rs2205960 1 173191474 173191475 - 
SLE SNP rs3135394 6 32408496 32408497 - 
SLE SNP rs10847697 12 129299384 129299385 SLC15A4 
SLE SNP rs2070197 7 128588999 128589000 IRF5  
SLE SNP rs4963128 11 589563 589564 PHRF1 
SLE SNP rs2280381 16 86018632 86018633 - 
SLE SNP rs1990760 2 163124050 163124051 IFIH1 
SLE SNP rs280519 19 10472932 10472933 TYK2 
SLE SNP rs1913517 10 50119053 50119054 LRRC18, WDFY4 
SLE SNP rs6445975 3 58370176 58370177 PXK  
SLE SNP rs849142 7 28185890 28185891 JAZF1 
SLE SNP rs11755393 6 34824635 34824636 UHRF1BP1 
SLE SNP rs6985109 8 10761584 10761585 XKR6  
SLE SNP rs396716 1 161514595 161514596 FCGR3A  
SLE SNP rs396991 1 161514541 161514542 FCGR3A  
SLE SNP rs445509 1 161512347 161512348 FCGR3A 
SLE SNP rs1042206 1 161512958 161512959 FCGR3A 
SLE SNP rs148181339 1 161518213 161518214 FCGR3A 
SLE SNP rs1050501 1 161643797 161643798 FCGR2B 
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SLE SNP rs1051009 17 4637885 4637886 CXCL16 
SLE SNP rs10752900 1 183086237 183086238 LAMC1 
FcRγ SNP rs10127939 1 161518332 161518333 FCGR3A  
FcRγ SNP rs145557772 1 161518233 161518234 FCGR3A  
FcRγ SNP rs396991 1 161514541 161514542 FCGR3A  
FcRγ SNP rs396716 1 161514595 161514596 FCGR3A  
FcRγ SNP rs443082 1 161514627 161514628 FCGR3A  
FcRγ SNP rs445509 1 161512347 161512348 FCGR3A  
FcRγ SNP rs1042206 1 161512958 161512959 FCGR3A  
FcRγ SNP rs148181339 1 161518213 161518214 FCGR3A  
FcRγ SNP rs1801274 1 161479744 161479745 FCGR2A  
FcRγ REGION rs428888 1 161548496 161548497 FCGR3A  
FcRγ REGION rs403016 1 161548632 161548633 FCGR3A  
FcRγ SNP rs1050501 1 161643797 161643798 FCGR2B 
FcRγ SNP rs6427598 1 161484563 161484564 FCGR2A  
FcRγ SNP rs368433 1 161484209 161484210 FCGR2A  
FcRγ REGION rs3219018 1 161581052 161581058 FCGR2B 
FcRγ SNP rs844 1 161647532 161647533 FCGR2B 
FcRγ SNP rs1674761 1 161645470 161645471 FCGR2B 
FcRγ SNP rs5017567 1 161641295 161641296 FCGR2B 
FcRγ SNP rs12118043 1 161646823 161646824 FCGR2B 
FcRγ SNP rs5030738 1 161599653 161599654 FCGR3B 
 
A.2 Hotspot files 
Acne 
Track name="CHP2_HotSpots" description="CHP2_COSMIC_Mutations_v60" type=bedDetail 
Chr Start End SNP REF Panel 
chr4 154626316 154626317 rs5743708 REF=G;OBS=A;ANCHOR=C acne 
chr9 120475301 120475302 rs4986790 REF=A;OBS=G;ANCHOR=G acne 
chr9 120475601 120475602 rs4986791 REF=C;OBS=T;ANCHOR=T acne 
chr6 31543100 31543101 rs361525 REF=G;OBS=A;ANCHOR=T acne 
chr6 31543030 31543031 rs1800629 REF=G;OBS=A;ANCHOR=T acne 
chr6 31542481 31542482 rs1799724 REF=C;OBS=T;ANCHOR=T acne 
chr6 31542475 31542476 rs1800630 REF=C;OBS=A;ANCHOR=C acne 
chr6 31542307 31542308 rs1799964 REF=T;OBS=C;ANCHOR=T acne 
chr2 113537222 113537223 rs17561 REF=C;OBS=A;ANCHOR=T acne 
chr15 75012984 75012985 rs1048943 REF=T;OBS=C;ANCHOR=T acne 
chr15 75011640 75011641 rs4646903 REF=A;OBS=G;ANCHOR=C acne 
chr10 104597151 104597152 rs743572 REF=A;OBS=G;ANCHOR=T acne 
chr8 128676130 128676131 rs4133274 REF=A;OBS=G;ANCHOR=T acne 
chr8 128691211 128691212 rs13248513 REF=T;OBS=C;ANCHOR=T acne 
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SLE 
Track name="CHP2_HotSpots" description="CHP2_COSMIC_Mutations_v60" type=bedDetail 
Chr Start End SNP REF Panel 
chr16 31313252 31313253 rs9888739 REF=C;OBS=T;ANCHOR=T sle 
chr6 106568033 106568034 rs548234 REF=C;OBS=T;ANCHOR=T sle 
chr6 138196065 138196066 rs2230926 REF=T;OBS=G;ANCHOR=T sle 
chr5 150457484 150457485 rs7708392 REF=G;OBS=C;ANCHOR=T sle 
chr22 21809184 21809185 rs463426 REF=T;OBS=C;ANCHOR=T sle 
chr11 128311058 128311059 rs6590330 REF=G;OBS=A;ANCHOR=T sle 
chr7 50305862 50305863 rs4917014 REF=T;OBS=G;ANCHOR=T sle 
chr11 35129171 35129172 rs507230 REF=G;OBS=A;ANCHOR=T sle 
chr4 102751075 102751076 rs10516487 REF=G;OBS=A;ANCHOR=T sle 
chr8 11340180 11340181 rs7812879 REF=T;OBS=C;ANCHOR=T sle 
chr8 56849385 56849386 rs7829816 REF=A;OBS=G;ANCHOR=T sle 
chr2 33701889 33701890 rs13385731 REF=T;OBS=C;ANCHOR=T sle 
chr1 183549756 183549757 rs10911363 REF=G;OBS=T;ANCHOR=T sle 
chr2 191964632 191964633 rs7574865 REF=T;OBS=G;ANCHOR=T sle 
chr1 114377567 114377568 rs2476601 REF=A;OBS=G;ANCHOR=T sle 
chr1 173191474 173191475 rs2205960 REF=G;OBS=T;ANCHOR=T sle 
chr6 32408496 32408497 rs3135394 REF=A;OBS=G;ANCHOR=T sle 
chr12 129299384 129299385 rs10847697 REF=G;OBS=A;ANCHOR=T sle 
chr7 128588999 128589000 rs2070197 REF=T;OBS=C;ANCHOR=T sle 
chr11 589563 589564 rs4963128 REF=T;OBS=C;ANCHOR=T sle 
chr16 86018632 86018633 rs2280381 REF=C;OBS=T;ANCHOR=T sle 
chr2 163124050 163124051 rs1990760 REF=C;OBS=T;ANCHOR=T sle 
chr19 10472932 10472933 rs280519 REF=A;OBS=G;ANCHOR=T sle 
chr10 50119053 50119054 rs1913517 REF=A;OBS=G;ANCHOR=T sle 
chr3 58370176 58370177 rs6445975 REF=G;OBS=T;ANCHOR=T sle 
chr7 28185890 28185891 rs849142 REF=T;OBS=C;ANCHOR=T sle 
chr6 34824635 34824636 rs11755393 REF=A;OBS=G;ANCHOR=T sle 
chr8 10761584 10761585 rs6985109 REF=G;OBS=A;ANCHOR=T sle 
chr1 161514595 161514596 rs396716 REF=A;OBS=G;ANCHOR=T sle 
chr1 161514541 161514542 rs396991 REF=A;OBS=C;ANCHOR=T sle 
chr1 161512347 161512348 rs445509 REF=C;OBS=T;ANCHOR=C sle 
chr1 161512958 161512959 rs1042206 REF=A;OBS=C;ANCHOR=A sle 
chr1 161518213 161518214 rs148181339 REF=T;OBS=C;ANCHOR=A sle 
chr1 161643797 161643798 rs1050501 REF=T;OBS=C;ANCHOR=A sle 
chr17 4637885 4637886 rs1051009 REF=G;OBS=A;ANCHOR=T sle 
chr1 183086237 183086238 rs10752900 REF=G;OBS=A;ANCHOR=T sle 
 
FcRγ 
Track name="CHP2_HotSpots" description="CHP2_COSMIC_Mutations_v60" type=bedDetail 
Chr Start End SNP REF Panel 
chr1 161518332 161518333 rs10127939 REF=A;OBS=C;ANCHOR=G FCGR 
chr1 161518233 161518234 rs145557772 REF=G;OBS=A;ANCHOR=C FCGR 
chr1 161514541 161514542 rs396991 REF=A;OBS=C;ANCHOR=A FCGR 
chr1 161514595 161514596 rs396716 REF=A;OBS=G;ANCHOR=T FCGR 
chr1 161514627 161514628 rs443082 REF=C;OBS=T;ANCHOR=G FCGR 
chr1 161512347 161512348 rs445509 REF=C;OBS=T;ANCHOR=C FCGR 
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chr1 161512958 161512959 rs1042206 REF=A;OBS=C;ANCHOR=A FCGR 
chr1 161518213 161518214 rs148181339 REF=T;OBS=C;ANCHOR=A FCGR 
chr1 161479744 161479745 rs1801274 REF=A;OBS=G;ANCHOR=C FCGR 
chr1 161548496 161548497 rs428888 REF=T;OBS=C;ANCHOR=T FCGR 
chr1 161548632 161548633 rs403016 REF=C;OBS=G;ANCHOR=C FCGR 
chr1 161643797 161643798 rs1050501 REF=T;OBS=C;ANCHOR=A FCGR 
chr1 161484563 161484564 rs6427598 REF=T;OBS=A;ANCHOR=G FCGR 
chr1 161484209 161484210 rs368433 REF=T;OBS=C;ANCHOR=A FCGR 
chr1 161581052 161581058 rs3219018 REF=G;OBS=C;ANCHOR=T FCGR 
chr1 161647532 161647533 rs844 REF=A;OBS=G;ANCHOR=T FCGR 
chr1 161645470 161645471 rs1674761 REF=A;OBS=C;ANCHOR=T FCGR 
chr1 161641295 161641296 rs5017567 REF=A;OBS=C;ANCHOR=C FCGR 
chr1 161646823 161646824 rs12118043 REF=C;OBS=A;ANCHOR=C FCGR 
chr1 161599653 161599654 rs5030738 REF=G;OBS=T;ANCHOR=A FCGR 
 
A.3 Sequencing summary statistics 
Sequenced genotypes per SNP 
Chr SNP n missing genotype n patients % missing genotype 
1 rs2476601 11 71 15.49% 
1 rs1801274 3 71 4.23% 
1 rs368433 5 71 7.04% 
1 rs6427598 3 71 4.23% 
1 rs445509 2 71 2.82% 
1 rs1042206 1 71 1.41% 
1 rs396991 3 71 4.23% 
1 rs396716 1 71 1.41% 
1 rs443082 3 71 4.23% 
1 rs148181339 1 71 1.41% 
1 rs145557772 3 71 4.23% 
1 rs10127939 71 71 100.00% 
1 rs5030738 15 71 21.13% 
1 rs5017567 3 71 4.23% 
1 rs1050501 71 71 100.00% 
1 rs1674761 29 71 40.85% 
1 rs12118043 5 71 7.04% 
1 rs844 3 71 4.23% 
1 rs2205960 11 71 15.49% 
1 rs10752900 8 71 11.27% 
1 rs10911363 45 71 63.38% 
2 rs13385731 36 71 50.70% 
2 rs17561 32 71 45.07% 
2 rs1990760 15 71 21.13% 
2 rs7574865 10 71 14.08% 
3 rs6445975 23 71 32.39% 
4 rs10516487 7 71 9.86% 
4 rs5743708 34 71 47.89% 
5 rs7708392 38 71 53.52% 
6 rs1799964 42 71 59.15% 
6 rs1800630/rs4645836 10 71 14.08% 
6 rs1799724 10 71 14.08% 
6 rs1800629 9 71 12.68% 
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6 rs361525 9 71 12.68% 
6 rs3135394 43 71 60.56% 
6 rs11755393 14 71 19.72% 
6 rs548234 32 71 45.07% 
6 rs2230926 8 71 11.27% 
7 rs849142 9 71 12.68% 
7 rs4917014 8 71 11.27% 
7 rs2070197 8 71 11.27% 
8 rs6985109 21 71 29.58% 
8 rs7812879 8 71 11.27% 
8 rs7829816 12 71 16.90% 
8 rs4133274 10 71 14.08% 
8 rs13248513 11 71 15.49% 
9 rs4986790 19 71 26.76% 
9 rs4986791 21 71 29.58% 
10 rs1913517 27 71 38.03% 
10 rs743572 24 71 33.80% 
11 rs4963128 16 71 22.54% 
11 rs507230 27 71 38.03% 
11 rs6590330 58 71 81.69% 
12 rs10847697 24 71 33.80% 
15 rs79812015/rs4646903 26 71 36.62% 
15 rs1048943 21 71 29.58% 
16 rs9888739 5 71 7.04% 
16 rs2280381 70 71 98.59% 
17 rs1051009 31 71 43.66% 
19 rs280519 15 71 21.13% 
22 rs463426 7 71 9.86% 
 
Sequenced genotypes per patient 
ID n missing genotypes n sequenced genotypes % missing genotypes 
20 61 61 100.00% 
90 14 61 22.95% 
213 17 61 27.87% 
281 27 61 44.26% 
344 14 61 22.95% 
375 27 61 44.26% 
406 46 61 75.41% 
428 30 61 49.18% 
566 28 61 45.90% 
586 41 61 67.21% 
598 12 61 19.67% 
624 40 61 65.57% 
638 23 61 37.70% 
708 34 61 55.74% 
750 33 61 54.10% 
796 20 61 32.79% 
10 23 61 37.70% 
75 19 61 31.15% 
102 23 61 37.70% 
200 19 61 31.15% 
234 8 61 13.11% 
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236 15 61 24.59% 
245 27 61 44.26% 
288 16 61 26.23% 
302 21 61 34.43% 
336 23 61 37.70% 
362 16 61 26.23% 
381 16 61 26.23% 
398 8 61 13.11% 
416 21 61 34.43% 
421 14 61 22.95% 
440 22 61 36.07% 
469 6 61 9.84% 
477 8 61 13.11% 
483 5 61 8.20% 
497 4 61 6.56% 
502 5 61 8.20% 
512 5 61 8.20% 
516 3 61 4.92% 
552 5 61 8.20% 
559 12 61 19.67% 
562 5 61 8.20% 
576 4 61 6.56% 
583 5 61 8.20% 
588 19 61 31.15% 
592 4 61 6.56% 
595 6 61 9.84% 
605 6 61 9.84% 
606 10 61 16.39% 
609 6 61 9.84% 
610 9 61 14.75% 
613 10 61 16.39% 
635 10 61 16.39% 
663 9 61 14.75% 
665 10 61 16.39% 
681 9 61 14.75% 
696 18 61 29.51% 
706 16 61 26.23% 
709 22 61 36.07% 
713 25 61 40.98% 
720 25 61 40.98% 
733 25 61 40.98% 
736 23 61 37.70% 
748 13 61 21.31% 
788 4 61 6.56% 
804 5 61 8.20% 
831 5 61 8.20% 
840 20 61 32.79% 
841 3 61 4.92% 
843 5 61 8.20% 
889 5 61 8.20% 
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A.4 Association analysis results 
Chr SNP 
p Hardy-
Weinberg 
p all 
patients 
p training set 
p validation 
set 
1 rs2476601 0.3953 0.3346 NA 0.3578 
1 rs1801274 0.2965 0.1337 0.4146 0.183 
1 rs368433 1.0000 NA NA NA 
1 rs6427598 0.3298 0.8631 1.0000 0.8075 
1 rs445509 1.0000 NA NA NA 
1 rs1042206 1.0000 NA NA NA 
1 rs396991 0.1769 0.6883 0.1638 0.6517 
1 rs396716 1.0000 NA NA NA 
1 rs443082 1.0000 NA NA NA 
1 rs148181339 1.0000 NA NA NA 
1 rs145557772 1.0000 NA NA NA 
1 rs10127939 1.0000 NA NA NA 
1 rs5030738 1.0000 0.7656 NA 0.5762 
1 rs5017567 1.0000 NA NA NA 
1 rs1050501 1.0000 NA NA NA 
1 rs1674761 1,51E-08 0.8936 NA 0.8445 
1 rs12118043 1.0000 0.4318 0.1877 0.7451 
1 rs844 1.0000 0.9228 0.3728 0.4894 
1 rs2205960 1.0000 0.7963 0.4366 0.8999 
1 rs10752900 0.8005 0.4304 0.2924 0.6770 
1 rs10911363 0.1303 0.5341 NA 0.6244 
2 rs13385731 1.0000 0.7914 NA 0.4698 
2 rs17561 0.6911 1.0000 NA 0.3211 
2 rs1990760 0.5525 0.8752 0.8801 0.9198 
2 rs7574865 0.5010 0.2592 0.2437 0.4797 
3 rs6445975 1.0000 0.2125 0.4397 0.4290 
4 rs10516487 0.5785 0.2985 0.7245 0.3371 
4 rs5743708 1.0000 0.3493 0.2722 0.9700 
5 rs7708392 1.0000 0.5232 NA 0.8659 
6 rs1799964 1.0000 0.4411 NA 0.9601 
6 rs1800630/rs4645836 0.5806 1.0000 0.2199 0.5821 
6 rs1799724 1.0000 0.6686 0.2666 0.6985 
6 rs1800629 1.0000 0.2511 0.8754 0.2504 
6 rs361525 1.0000 0.6478 NA 0.7264 
6 rs3135394 1.0000 0.6445 NA 0.6516 
6 rs11755393 0.7853 0.1068 0.1996 0.3059 
6 rs548234 0.3124 0.166 0.7698 0.1256 
6 rs2230926 1.0000 0.3891 NA 0.3691 
7 rs849142 0.4356 0.003621 0.00395 0.04362 
7 rs4917014 0.5478 0.835 1.0000 0.8655 
7 rs2070197 1.0000 0.2922 0.8154 0.3069 
8 rs6985109 0.5629 1.0000 0.6667 0.7741 
8 rs7812879 0.5965 0.4808 0.2413 0.8298 
8 rs7829816 1.0000 0.1979 0.4071 0.3193 
8 rs4133274 1.0000 1.0000 0.2199 0.5762 
8 rs13248513 1.0000 0.8089 0.2199 0.4076 
9 rs4986790 1.0000 0.1637 NA 0.1635 
9 rs4986791 1.0000 0.7494 0.4816 0.3997 
10 rs1913517 0.7621 1.0000 0.4366 0.7776 
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10 rs743572 1.0000 0.1561 0.9001 0.1262 
11 rs4963128 0.0413 0.3063 0.2509 0.5945 
11 rs507230 1.0000 0.1334 1.0000 0.1097 
11 rs6590330 0.2092 0.2706 NA 0.8028 
12 rs10847697 0.09936 0.5425 0.495 0.9548 
15 rs79812015/rs4646903 1.0000 0.3138 NA 0.3746 
15 rs1048943 1.0000 0.3765 NA 0.4071 
16 rs9888739 0.6566 0.8668 0.2345 0.3694 
16 rs2280381 1.0000 NA NA NA 
17 rs1051009 0.3535 0.465 0.4778 0.6102 
19 rs280519 0.05934 0.6209 0.4636 0.9892 
22 rs463426 1.0000 0.009854 0.0663 0.03559 
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A.5 Linkage Disequilibrium Plot of SNPs in JAZF1 gene 
 
